Vaccine IP monitoring that produces evidence, not dashboard screenshots
When patent activity moves around vaccine or biologics programs, LocusTrace turns public coverage drift into reproducible evidence packets that counsel and R&D can inspect offline.
Informational evidence infrastructure only. Not legal advice, not infringement analysis, not FTO.
- • vaccine patent litigation monitoring
- • mRNA vaccine patent monitoring
- • biologics IP monitoring
- • patent litigation evidence packet
Start weekly, then tighten cadence for volatile programs if production monitoring converts.
Each run declares what was checked, what changed, and which artifacts support the result.
A free 2-week trial proves whether the evidence loop is useful before production purchase.
Why this page exists
The point is not to make legal conclusions. The point is to make technical evidence easier to review, forward, and verify.
- • Counsel-ready packet index
- • R&D-readable report
- • Machine-readable alert summary
LocusTrace is strongest when repeated reviews matter: new publications, family changes, sequence-listing updates, and watchlist drift.
- • Run-to-run comparison
- • Declared corpus scope
- • Deterministic output structure
The free trial creates concrete artifacts before the production-key decision, so the buying case is based on outputs.
- • Free trial first
- • Production key after proof
- • Enterprise deployment when required
Frequently asked questions
No. LocusTrace is evidence infrastructure for patent-sequence monitoring. It can support litigation-aware review workflows, but it does not provide legal conclusions.
It can help technical and IP teams assemble reproducible monitoring artifacts. Legal strategy and conclusions remain with counsel.
A production key keeps monitoring live with cadence, watchlist volume, deployment model, and operator workflow sized to the team.
Yes. The workflow emphasizes deterministic packet structure, manifest hashes, and offline verification paths.
Bring one watchlist. Leave with evidence.
The trial is scoped around synthetic/demo-safe target sequences, IDs, motifs, or a watchlist definition. The commercial decision comes after the artifacts prove useful.